Oncolytics Biotech Inc.’s Research Collaborators to Present REOLYSIN® Trial Data at ASCO Conference
Thursday 16 March 2006
Research Collaborators with Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) are scheduled to deliver two poster presentations covering REOLYSIN® clinical trial data at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 2-6 2006 in Atlanta, Georgia. The data cover interim results of Oncolytics’ Phase I systemic administration trial being conducted in the U.K., and final results of Oncolytics’ Canadian Phase I recurrent malignant glioma trial.
A poster entitled “A Phase I study of a wild-type reovirus (Reolysin) given intravenously to patients with advanced malignancies” is scheduled to be presented by Dr. Johann S. de Bono of The Royal Marsden Hospital and The Institute of Cancer Research, U.K.
A poster entitled “A Phase I trial of intratumoural (i.t.) administration of reovirus (Reolysin®) in patients with histologically confirmed recurrent malignant gliomas (MGs)” is scheduled to be presented by Dr. P.A. Forsyth of the University of Calgary and the Alberta Cancer Board.
- ends -
For further information please contact:
Oncolytics Biotech Inc.
210, 1167 Kensington Cr NW
Calgary, Alberta T2N 1X7
The Equicom Group
20 Toronto Street
Toronto, Ontario M5C 2B8
Tel: 416.815.0700 ext.22
The Investor Relations Group
11 Stone St, 3rd Floor
New York, NY 10004
RenMark Financial Communications
2080 Rene Levesque Blvd. W.
Montreal, PQ H3H 1R6
Notes to editors:
- About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I and Phase I/II human trials using REOLYSIN®, its proprietary formulation of the human reovirus, alone and in combination with radiation. For further information about Oncolytics, please visit www.oncolyticsbiotech.com
- This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN®, the Company’s expectations related to the results of trials investigating delivery of REOLYSIN®, and the Company’s belief as to the potential of REOLYSIN® as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN® as a cancer treatment, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize REOLYSIN®, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.